Avastin Associated With Risk of Serious Arterial Thromboembolic Events

"The U.S. Food and Drug Administration (FDA) and Genentech, Inc., sent a letter yesterday to healthcare professionals that warns of the risk for serious and fatal arterial thromboembolic events related to the use of bevacizumab (Avastin) in patients with metastatic colorectal cancer."